A safety panel of the European drug regulator on January 14 recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca’s COVID-19 vaccine.
Europe’s drug regulator on November 11 recommended adding a rare type of spinal inflammation called transverse myelitis as a side effect of Johnson & Johnson’s single-dose Covid-19 vaccine.
The U.S. Food and Drug Administration accepted for Priority Review Pfizer Inc.’s Biologics License Application for TicoVac, the company’s tick-borne encephalitis vaccine for active immunization to prevent TBE in individuals 1 year of age and older.
The U.S. Food and Drug Administration approved Novartis’ Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis.
A new medical device for treating scoliosis – curvature of the spine – received FDA approval, providing an alternative that both corrects the curve and maintains flexibility in the spine.
The U.S. Food and Drug Administration approved Allergan plc’s supplemental biologics application for Botox for the treatment of pediatric patients (2 to 17 years of age) with upper limb spasticity.
Eli Lilly announced the results of the company’s COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat ankylosing spondylitis. The study met both primary and major secondary endpoints.
Scientists have for the first time fixed a protein defect that causes Huntington’s disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.
X-Spine Systems, a division of Xtant Medical Systems, is shutting down a facility in Ohio and terminating 54 people between December and February 2018.
DePuy Synthes Products Inc., part of the Johnson & Johnson Medical Devices Companies, announced today that it has acquired Innovative Surgical Solutions LLC, doing business as Sentio LLC.